Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Better Prognosis of Multiple Sclerosis in Patients Who Experienced a Full-Term Pregnancy.
Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1.
Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis.
Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study.
Genzyme submits applications to FDA and EMA for approval of LEMTRADA™ (alemtuzumab) for multiple sclerosis
Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.
Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review.
URMC rheumatologist presents data showing drug’s potential to ease arthritis symptoms
Study hints of rituximab MS benefit
Oral Laquinimod for Multiple Sclerosis Granted Fast Track Status by FDA
The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-β expression via peroxisome proliferator-activated receptor-α
Role of the Blood-Brain Barrier in Multiple Sclerosis.
Brain reserve and cognitive reserve in multiple sclerosis: What you've got and how you use it.
A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
HL-A antigens and multiple sclerosis.
Imaging robust microglial activation after lipopolysaccharide administration in humans with PET.
A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
Subcutaneous IFN-β1a to treat relapsing-remitting multiple sclerosis.
Momenta Pharmaceuticals Announces FDA Approval of ANDA for Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for COPAXONE(R) (glatiramer acetate injection) 20mg
Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study.
Therapeutic class review, Neurological - multiple sclerosis dalfampridine (Ampyra(TM))
Restoration of axon conduction and motor deficits by therapeutic treatment with glatiramer acetate.
Optimizing IFN Beta - 1B Dose (Optims)
UPDATE 1-Teva Pharmaceutical banks on thrice-weekly Copaxone
Mitoxantrone for multiple sclerosis.

Pages